Core Viewpoint - Meino Bio's stock performance shows a slight increase, with significant financing activity indicating a high level of investor interest and engagement in the company's shares [1][2]. Financing Summary - On January 26, Meino Bio's financing buy-in amounted to 4.726 million yuan, while financing repayment was 6.1917 million yuan, resulting in a net financing buy-in of -1.4656 million yuan [1]. - The total financing and securities balance for Meino Bio reached 48.3309 million yuan, representing 1.75% of its circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high financing balance [1]. - The company had no short selling activity on January 26, with a short selling balance of 27,500 yuan and a remaining short selling volume of 1,400 shares, which is above the 90th percentile level over the past year, indicating a high level of short interest [1]. Business Performance - As of September 30, Meino Bio reported a total of 10,400 shareholders, a decrease of 17.92% from the previous period, while the average circulating shares per person increased by 21.83% to 7,161 shares [2]. - For the period from January to September 2025, Meino Bio achieved operating revenue of 390 million yuan, reflecting a year-on-year growth of 14.68%, and a net profit attributable to shareholders of 40.9182 million yuan, which is a 29.44% increase year-on-year [2]. Dividend and Shareholding - Since its A-share listing, Meino Bio has distributed a total of 168 million yuan in dividends [3]. - As of September 30, 2025, among the top ten circulating shareholders, the Guotai CSI Animal Husbandry ETF ranked as the sixth largest shareholder with 1.1559 million shares, an increase of 334,500 shares from the previous period [3]. - The Nuoan Multi-Strategy Mixed A fund entered as a new shareholder, holding 861,800 shares, while the Jianxin Flexible Allocation Mixed A fund also entered as a new shareholder with 448,700 shares [3].
美农生物1月26日获融资买入472.60万元，融资余额4830.34万元